stockrow
Saturday 7 November 2026
Export QTTB’s income statement to Excel — free account
Q32 Bio Inc.
QTTB Healthcare Biotechnology
Q32 Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.7 million.
- EPS
- +43.6%
- Free cash flow
- +71.1%
- Total debt
- −35.6%
Quarter to June 2026, against a year earlier
9.25
0.40
+4.52%
Follow QTTB
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
55,030.07% | 125.06% | 157.18% | 72.14% | |
| (51.87%) | 38.70% | 46.58% | 37.13% | ||
ROIC |
0.00% | (672.17%) | (540.26%) | 0.00% | |
Return on Tangible Assets |
(103.26%) | 66.74% | 70.10% | 32.16% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(3.17) | (2.16) | (1.94) | (0.97) | |
Free Cash Flow |
(38.79) | (26.62) | (27.40) | (19.83) | |
Capital Expenditures |
— | 6.93 | — | — | |
| Other line items | |||||
Cash ROIC |
(92.75%) | (26.61%) | (26.04%) | (9.35%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.92 | (1.12) | (0.82) | (0.59) | |
Depreciation/Fixed assets |
0.57 | 0.58 | 0.59 | 0.50 | |
Capex/Depreciation |
0.00 | 12.13 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.17) | (2.73) | (1.94) | (0.97) | |
Capex per Share |
0.00 | 0.56 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | — | — |
Columns are period end dates · fundamentals updated 26 Oct 2026